Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients

Paricalcitol Action on Parameters of Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease Stage Vd Carriers Tunneled Hemodialysis Catheters

Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of inflammatory and oxidative stress parameters.

Use of Paricalcitol in stage Vd Chronic Kidney Disease patients using a permanent catheter due to haemodialysis; over the effect of inflammatory and oxidative stress parameters. This study uses paricalcitol (vitamin D) versus atorvastatin versus paricalcitol plus atorvastatin treatments.

Inclusion Criteria:

• Vd CKD patients using haemodialysis during 3 or more months.
• Tunnelized-bearer permanent catheters on haemodialysis at last 6 months previous at the beginning of the study. .
• Kt stable, over 45 litres on both sexs.
• Patients in treatment wiht atorvastatin
• Patients without infectious or inflammatory processes over 8 weeks.
• Two consecutive PTH < than 400 pg/ml; Ca<10.2 and P <7.0 mg/dl.

Exclusion Criteria:

• Patients > 18 years.
• Pregnant women.
• Patients hospitalized 4 weeks before the beginning of the treatment.
• Immunosuppressor intake.